Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;41(7):1523-1531.
doi: 10.1111/liv.14713. Epub 2020 Nov 16.

Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry

Judith Sanabria-Cabrera  1   2 , Rocío Sanjuán-Jiménez  1   2 , Encarnación Clavijo  3 , Inmaculada Medina-Cáliz  2 , Andrés González-Jiménez  2 , Miren García-Cortés  2   4 , Aida Ortega-Alonso  2 , Miguel Jiménez-Pérez  5 , Rocío González-Grande  5 , Camilla Stephens  2   4 , Mercedes Robles-Díaz  2   4 , M Isabel Lucena  1   4 , Raúl J Andrade  2   4 ; Spanish DILI Registry
Affiliations

Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry

Judith Sanabria-Cabrera et al. Liver Int. 2021 Jul.

Abstract

Background and aims: Drug-induced liver injury (DILI) presents with a wide phenotypic spectrum requiring an extensive differential diagnosis. Hepatitis E virus (HEV) is not systematically ruled out during acute hepatitis assessment in Spain. The aims of this study were to establish the role of HEV infection and its phenotypic presentation in patients initially suspected of DILI and to determine the anti-HEV seroprevalence rate.

Methods: An analysis of 265 patients with suspected DILI and considered for enrolment in the Spanish DILI Registry and 108 controls with normal liver profiles was undertaken. Anti-HEV Immunoglobulin (Ig) G antibodies were analysed in serum from all subjects. In those with serum samples extracted within 6 months from liver damage onset (n = 144), HEV antigen (Ag) and anti-HEV IgM antibodies were tested in duplicate by ELISA. In addition, RT-PCR was performed externally in eight patients.

Results: Out of 144 patients, 12 (8%) were positive for anti-HEV IgM, mean age was 61 years. Underlying hepatic diseases (OR = 23.4, P < .001) and AST peak >20 fold upper limit of normal (OR = 10.9, P = .002) were associated with the diagnosis of acute hepatitis E. The overall anti-HEV IgG seroprevalence rate was 35%, evenly distributed between patients with suspected DILI (34%), and controls (39%).

Conclusions: HEV seroprevalence and acute hepatitis E rates are relatively high in Spain. A search for active HEV infection is therefore advised in patients assessed for suspicion of DILI, particularly in patients with underlying liver diseases and high transaminase levels.

Keywords: acute hepatitis E virus infection; acute hepatitis assessment; drug-induced liver injury; seroprevalence rate.

PubMed Disclaimer

References

REFERENCES

    1. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26:1429-1435.
    1. Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141:1665-1672.
    1. Pérez-gracia MT, García M, Suay B, Mateos-Lindemann ML. Current knowledge on hepatitis E. J Clin Transl Hepatol. 2015;3:117-126.
    1. Capai L, Charrel R, Falchi A. Hepatitis e in high-income countries: What do we know? and what are the knowledge gaps? Viruses. 2018;10:E285.
    1. Kokki I, Smith D, Simmonds P, et al. Hepatitis E virus is the leading cause of acute viral hepatitis in Lothian, Scotland. New Microbes New Infect. 2016;10:6-12.

Publication types

LinkOut - more resources